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ABSTRACT
Introduction: To compare both the prevalence of gestational diabetes mellitus (GDM) as well as
maternal and neonatal outcomes by either the one-step or the two-step approaches.
Material and methods: Electronic databases were searched from their inception until
June 2017. We included all randomized controlled trials (RCTs) comparing the one-step with the
two-step approaches for the screening and diagnosis of GDM. The primary outcome was the
incidence of GDM.
Results: Three RCTs (n¼ 2333 participants) were included in the meta-analysis. 910 were
randomized to the one step approach (75g, 2 hrs), and 1423 to the two step approach. No sig-
nificant difference in the incidence of GDM was found comparing the one step versus the two
step approaches (8.4 versus 4.3%; relative risk (RR) 1.64, 95%CI 0.77–3.48). Women screened with
the one step approach had a significantly lower risk of preterm birth (PTB) (3.7 versus 7.6%; RR
0.49, 95%CI 0.27–0.88), cesarean delivery (16.3 versus 22.0%; RR 0.74, 95%CI 0.56–0.99), macroso-
mia (2.9 versus 6.9%; RR 0.43, 95%CI 0.22–0.82), neonatal hypoglycemia (1.7 versus 4.5%; RR
0.38, 95%CI 0.16–0.90), and admission to neonatal intensive care unit (NICU) (4.4 versus 9.0%; RR
0.49, 95%CI 0.29–0.84), compared to those randomized to screening with the two step approach.
Conclusions: The one and the two step approaches were not associated with a significant differ-
ence in the incidence of GDM. However, the one step approach was associated with better
maternal and perinatal outcomes.
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Introduction
Carbohydrates disorders, including gestational diabetes
mellitus (GDM) and pregestational diabetes mellitus
(DM), are common morbidities in pregnancy, with short-
and long-term consequences to mothers, fetuses, and
newborns. It has been estimated that about 6–18% of
all pregnancies are complicated by DM in pregnancy
[1–6]. The last report from the International Diabetes
Federation (IDF) estimate that worldwide, approxi-
mately 1 in 7 births in 2015 were complicated by some
form of hyperglycemia during pregnancy [7].
Management for women with GDM includes diet,
physical activity, oral hypoglycemic agents and/or insu-
lin as needed [6,8]. The management of women with
GDM is aimed at achieving best possible glycemic con-
trol, with normal or near normal glucose values, while
avoiding hypoglycemia [4–6]. This management is
effective in reducing maternal and neonatal morbidity
and mortality [6,7]. Nevertheless, worldwide controversy
exists regarding the best approach and criteria for GDM
screening and diagnosis (Table 1) [6,7,15–25]. Several
randomized controlled trials (RCTs), comparing the one
step versus the two step approaches for GDM screening
and diagnosis, have been published so far [22–24].
The aim of this systematic review and meta-analysis
of RCTs was to compare the incidence of GDM, as well
as the maternal and neonatal outcomes, by the one
step versus the two step approaches.
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Materials and methods
This review was performed according to a protocol
designed a priori and recommended for systematic
review [26]. Electronic databases (i.e. Medline, Scopus,
ClinicalTrials.gov, EMBASE, ScienceDirect, the Cochrane
Library at the CENTRAL Register of Controlled Trials,
SCIelo) were searched from their inception until
January 2017. Search terms used were the following
text words: “diabetes”, “trial”, “screening”, “diagnosis”,
“one-step”, “two-step”, “guidelines”, “review”,
“randomized”, and “clinical trial”. No restrictions for
language or geographic location were applied. In add-
ition, the reference lists of all identified articles were
examined to identify studies not captured by elec-
tronic searches. The electronic search and the eligibil-
ity of the studies were independently assessed by two
authors (GS, CC). Differences were discussed with a
third reviewer (VB).
We included all RCTs comparing the one step ver-
sus the two step approaches for screening and diag-
nosis of GDM. Quasi RCTs (i.e. trials in which allocation
was done on the basis of a pseudorandom sequence,
e.g. odd/even hospital number or date of birth, alter-
nation) were excluded.
The risk of bias in each included study was assessed
by using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions.
Seven domains related to risk of bias were assessed in
each included trial since there is evidence that these
issues are associated with biased estimates of treat-
ment effect: (1) random sequence generation; (2) allo-
cation concealment; (3) blinding of participants and
personnel; (4) blinding of outcome assessment; (5)
incomplete outcome data; (6) selective reporting; and
(7) other bias. Review authors’ judgements were cate-
gorized as “low risk”, “high risk” or “unclear risk” of
bias [26].
Two authors (GS, CC) independently assessed inclu-
sion criteria, risk of bias and data extraction.
Disagreements were resolved by discussion with a
third reviewer (VB). All analyses were done using an
intention-to-treat approach, evaluating women accord-
ing to the screening group to which they were ran-
domly allocated in the original trials. Primary and
secondary outcomes were defined before data extrac-
tion. All authors of the original trials were contacted
for missing data.
The primary outcome was the incidence of GDM.
Secondary outcomes were gestational weight gain
(GWG) from randomization to delivery (in grams), ges-
tational hypertension and preeclampsia (as defined by
the original trial), preterm birth (PTB)< 37 weeks,
induction of labor, shoulder dystocia (as defined by
the original trial), cesarean delivery, and perinatal out-
comes including birth weight, stillbirth (i.e. fetal death
>23 weeks), macrosomia (i.e. birth weight 4000
grams), large for gestational age (LGA) (i.e. birthweight
>90th percentile), small for gestational age (SGA) (i.e.
birthweight <10th percentile), neonatal hypoglycemia
(i.e. glucose <40mg/dL), neonatal hyperbilirubinemia
(i.e. total serum bilirubin >5mg/dL), admission to neo-
natal intensive care unit (NICU), and neonatal death
(i.e. death of a liveborn baby within the first 28 days
of life). We also planned to assess cost-analysis com-
paring the two screening methods.
The data analysis was completed independently by
two authors (GS, CC) using Review Manager v. 5.3 (The
Nordic Cochrane Centre, Cochrane Collaboration, 2014,
Copenhagen, Denmark). The completed analyses were
then compared, and any difference was resolved by
discussion with a third reviewer (VB).
Data from each eligible study were extracted with-
out modification of original data onto custom-made
data collection forms. For continuous outcomes
Table 1. Criteria for gestational diabetes mellitus screening by selected societies.
Test
Number of abnormal
values required
for diagnosis
Fasting
glucose
(mg/dL)
1 hour after
loading
(mg/dL)
2 hours after
loading
(mg/dL)
3 hours after
loading
(mg/dL)
ACOG, 2013 C&C [6] 2 step 3 h 100 g 2 95 180 155 140
ACOG, 2013 NDDG [6] 2 step 3 h 100 g 2 105 190 165 145
ADA, 2017 75g [9] 1 step 2 h 75 g 2 95 180 155 Not required
ADA, 2017 100g [9] 2 step 3 h 100 g 2 95 180 155 140
CDA, 2013 [10] 2 step 2 h 75 g 2 95 191 160 Not required
FIGO, 2013 [11] 1 step 2 h 75 g 1 92 180 153 Not required
IADPSG, 2015 [7] 1 step 2 h 75 g 1 92 180 153 Not required
NICE/RCOG, 2015 [12] 1 step 2 h 75 g 1 101 Not required 140 Not required
WHO, 1999 [13] 1 step 2 h 75 g 1 126 Not required 200 Not required
WHO, 2013 [14] 1 step 2 h 75 g 1 92 180 153 Not required
ACOG: American College of Obstetricians and Gynecologists; ADA: American Diabetes Association; CDA: Canadian Diabetes Association; C&C: Carpenter
and Coustan; IADPSG: International Association of Diabetes Pregnancy Study Group; NICE: National Institute for Health and Care Excellence; RCOG: Royal
College of Obstetricians and Gynaecologists; NDDG: National Diabetes Data Group; WHO: World Health Organization.
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means ± standard deviation was extracted and
imported into Review Manager v. 5.3.
Meta-analysis was performed using the random
effects model of DerSimonian and Laird, to produce
summary treatment effects in terms of mean difference
(MD) or relative risk (RR) with 95% confidence interval
(CI). Heterogeneity was measured using I-squared
(Higgins I2). A subgroup analysis for the primary and
the secondary outcomes was performed comparing the
one step with 75 g 2 hours test using the International
Association of Diabetes and Pregnancy Study Group
(IADPSG) criteria, versus the two step with 50 g 1 hour
followed for abnormals by the 3 h 100 g test using the
Carpenter and Coustan (C&C) criteria.
Potential publication biases were assessed statistic-
ally by using Begg’s and Egger’s tests. The meta-ana-
lysis was reported following the Preferred Reporting
Item for Systematic Reviews and Meta-analyses
(PRISMA) statement [26]. Before data extraction was
completed, the review was registered with the
PROSPERO International Prospective Register of
Systematic Reviews (CRD42017060752).
Results
Three RCTs [22–24] (n¼ 2333 participants) were identi-
fied as relevant and included in the meta-analysis
(Figure 1, Table 2). Publication bias, assessed statistic-
ally by using Begg’s and Egger’s tests, showed no sig-
nificant bias (p¼ .37 and p¼ .31, respectively). All
authors kindly provided additional unpublished data
from their trial. The entire database from one trial was
also obtained [23].
The overall risk of bias was low. All studies had low
risk of bias in “random sequence generation”, and
used opaque randomized envelopes. The randomiza-
tion sequence was computer-generated by a statisti-
cian. Adequate methods for allocation of women were
used in all the trials. Given the intervention, no trial
was double-blind (Figure 2). The statistical heterogen-
eity within the study ranged from low to moderate
with I2¼ 65% for the primary outcome, and I2¼ 0% for
most of the secondary outcomes.
Out of the 2333 women included in the review, 910
were randomized to the one step approach (2hrs, 75g),
Records idenﬁed through 
database searching 
(n = 96)
Sc
re
en
in
g 
In
cl
ud
ed
 
El
ig
ib
ili
ty
 
Id
en

ﬁc
a
on
 
Addional records idenﬁed 
through other sources 
(n = 0)
Records aer duplicates removed 
(n = 80) 
Records screened 
(n = 80) 
Records excluded on the 
basis of tle or abstract 
(n = 74)
Full-text arcles assessed 
for eligibility 
(n = 7)
Full-text arcles excluded, 
with reasons 
Ongoing trial (n=1) 
Prior meta-analysis (n=1) 
No RCT (n=2) 
Studies included in 
qualitave synthesis 
(n = 3)
Studies included in 
quantave synthesis 
(meta-analysis) 
(n = 3) 
Figure 1. Flow diagram of studies identified in the systematic review. (Prisma template [Preferred Reporting Item for Systematic
Reviews and Meta-analyses]).
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and 1423 to the two step approach (Table 1).
Regarding the two step approach, one trial used 50g
1hr followed by 100g 3hrs [23]; in one trial all women
had 50g 1hr test before randomization and were
excluded if glucose 200mg/dL and then women in
the control group received 100g 3hrs [24]; finally,
Meltzer et al. [22] was a three arms trial with two con-
trol groups: two step 50g 1hour followed by 100g
3hrs, and two step 50g 1hour followed by 75g
2hours. For this review, both control groups of this trial
[22] were considered as control group (Table 3).
Data about diabetes management were available
for two RCTs. Both studies used four blood glucose
measurements per day, fasting and 1 hour after main
meals; glucose cutoff values were 95mg/dL fasting
and 140mg/dL 1 hour after meals. Management
differed on cutoffs for change from diet to pharmaco-
logic therapy, type of initial therapy, criteria for dose
adjustment and criteria for modify therapy. Meltzer
[22] gave precise indications on management, while
Scifres [24] preferred changes based on clinician
judgement (Table 4).
Tables 5 and 6 show the primary and the secondary
outcomes. No significant difference in the incidence of
GDM was found comparing the one step versus the
two step approach (8.4 versus 4.3%; RR 1.64, 95%CI
0.77–3.48; Figure 3). Women screened with the one
step approach had a significantly lower risk of PTB,
cesarean delivery, macrosomia, LGA, NICU admission,
and neonatal hypoglycemia, compared to those
randomized to the screening with the two step
approach (Tables 5 and 6). Moreover, women in the
Table 2. Characteristics of the included trials.
Location Population screened
Timing of
screening
Risk factors for
early screening
Fasting or not
fasting state
at screening Sample sizea
Meltzer,
2010 [22]
Canada All pregnant women without
pregestational DM
24–28 weeks Presence of multiple
risk factorsb
Fasting 1500 (500 versus 1000)
Sevket,
2014 [23]
Turkey Singleton gestations without
pregestational DM
24–28 weeks Not stated Fasting 786 (386 versus 400)
Scifres,
2015 [24]
USA Spontaneous-conceived, single-
ton gestations without pre-
gestational DM
18–24 weeks Not stated Fasting 47 (24 versus 23)
aNumber in the one step versus number in the two step group.
bAccording to the Canadian Diabetes Association 21.
DM: diabetes mellitus.
Figure 2. Assessment of risk of bias. (A) Summary of risk of bias for each trial; Plus sign: low risk of bias; minus sign: high risk of
bias; question mark: unclear risk of bias. (B) Risk of bias graph about each risk of bias item presented as percentages across all
included studies.
1550 G. SACCONE ET AL.
one step group had also a lower birth weight of about
135 grams (Table 6). Given that only one trial [22]
compared the two screening approaches in terms of
costs, pooled data for this outcome were not available.
Subgroup analysis was performed for primary and
secondary outcomes excluding Meltzer et al. [22],
which was slightly different from the other two RCTs
in terms of inclusion criteria (i.e. inclusion of also mul-
tiple gestations) and in terms of GDM screening crite-
ria (Table 2). The subgroup analysis for the primary
outcome revealed that the one step approach with
75 g 2 hours test using the IADPSG criteria was associ-
ated with a significant increase in the incidence of
GDM compared to the two step approach with 50 g
1 hour followed for abnormals by the 3 h 100 g test
using the C&C criteria (13.9 versus 5.7%; RR 2.43,
95%CI 1.54–3.82; Figure 4). This Meltzer trial [22] did
not contribute data to quantitative meta-analysis for
the secondary outcomes. Therefore, like in the main
analysis, the one step approach with 75 g 2 hours test
using the IADPSG criteria was associated with signifi-
cantly lower risks of PTB, cesarean delivery, macroso-
mia, LGA, NICU admission, and neonatal hypoglycemia,
as well as significantly lower birth weight compared to
the two step approach with 50 g 1 hour followed for
abnormals by the 3 h 100 g test using the C&C criteria
(Tables 5 and 6) [23,24].
Discussion
This meta-analysis from three RCTs showed that
screening women with the one step approach was
associated with a nonsignificant difference in the inci-
dence of GDM, compared to the two step approach.
However, our study provides evidence that the one
step approach is associated with better maternal and
perinatal outcomes, including significantly lower risks
of PTB, cesarean delivery, macrosomia, LGA, neonatal
hypoglycemia, admission to NICU, and lower mean
birth weight. Moreover, even if not statistically signifi-
cant, in many other secondary outcomes, which were
probably underpowered as uncommon, we found a
nonsignificant trend for benefit in the one step group
(Tables 5 and 6). When comparing the one step with
75 g 2 hours test using the IADPSG criteria (as recom-
mended currently by IADPSG [7], FIGO [11], and WHO
[13]), versus the two step with 50 g 1 hour followed for
abnormals by the 3 h 100 g test using C&C criteria
Table 3. Study design of the included trials.
Study group Study group cutoffs Control group (1) Control group cutoffs Control group (2)
Meltzer, 2010 [22] One step
(2 hrs, 75 g)
CDA: fasting 95mg/dL;
1 h 190mg/dL; 2 h
160mg/dL
Two step (50 g 1 hr;
100 g 3 hrs)
NDDG: fasting 105mg/dL; 1 h
190mg/dL; 2 h 165mg/dL;
3 h 145mg/dL
Two step (50 g 1 hr;
75 g 2 hrs)
Sevket, 2014 [23] One step
(2 hrs, 75 g)
IADPSG: fasting 92mg/
dL; 1 h 180mg/dL; 2 h
153mg/dL
Two step (50 g 1 hr;
100 g 3 hrs)
C&C: fasting 95mg/dL; 1 h
180mg/dL; 2 h 155mg/dL;
3 h 140mg/dL
–
Scifres, 2015 [24]a One step
(2 hrs, 75 g)
IADPSG: fasting 92mg/
dL; 1 h 180mg/dL; 2 h
153mg/dL
Two step (50 g 1 h; 100 g
3 h)
C&C: fasting 95mg/dL; 1 h
180mg/dL; 2 h 155mg/dL;
3 h 140mg/dL
–
aAll women in this study first had a 50 g 1 hr test before randomization and were excluded if glucose 200mg/dl.
CDA: Canadian Diabetes Association; NDDG: National Diabetes Data Group; IADPSG: International Association of Diabetes and Pregnancy Study Group;
C&C: Carpenter and Coustan.
Table 4. Diabetes management and primary outcome.
Meltzer, 2010 [22] Sevket, 2014 [23] Scifres, 2015 [24]
Management Frequency of glucose testing Prebreakfast and 1 h after meals
(QID)a
Not stated 4x/day; fasting and 1 hr ppa
Glucose target values Fasting 75–95 1h PC meal 140a Not stated Fasting <95mg/dL;
1 hr pp <140mg/dLa
Cutoffs for change from diet
to therapy
As above for 3 days in a row or 4/7
daysa
Not stated Per clinician judgementa
Type of initial therapy Lifestyle followed by insulin PRNa Not stated Glyburide or insulina
Dose and frequency of initial
therapy
NPH HS 4–10 units or premeal 2–4
units to starta
Not stated Per clinician judgementa
Criteria for pharmacologic
therapy dose adjustment
Patients given adjustment algorithm
for q2d changes if not at targeta
Not stated Per clinician judgementa
Criteria for adding or switch-
ing pharmacologic therapy
Only switch was lifestyle to insulin if
not at targetsa
Not stated Per clinician judgementa
Primary outcome Costs of screening and maternal and
neonatal outcomes for overall
study
Maternal and
neonatal outcomes
Maternal and neonatal
outcomes
aAdditional unpublished data kindly obtained by the original authors.
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(as recommended currently by ACOG [6] and ADA [9]),
the one step with IADPSG criteria was associated with
significantly higher incidence of GDM (13.9 versus
5.7%), and significantly lower risk of PTB, cesarean
delivery, macrosomia, LGA, neonatal hypoglycemia,
admission to NICU, and lower mean birth weight
(Tables 5 and 6).
This may be the first meta-analysis of RCTs compar-
ing the one with the two step approach for screening
of GDM. A prior Cochrane review by Farrar et al. aimed
to evaluate and compare different testing strategies
for diagnosis of GDM to improve maternal and infant
health while assessing their impact on healthcare ser-
vice costs [27]. Six small RCTs, including 694 women,
were analyzed. However, none of these included stud-
ies compared one versus two step approach and
therefore this analysis was not carried out [27].
Only three RCTs were included in our meta-analysis.
The largest one [22], did not report data on maternal
and perinatal outcomes and therefore the second larg-
est trial [23], drives the statistics in terms of maternal
and benefits for the one step approach. This is the
major shortcoming of our meta-analysis. Meltzer et al.
[22] was slightly different from the other two in terms
of inclusion criteria (i.e. inclusion of also multiple ges-
tations) and in terms of GDM screening criteria, and
also had two different control groups (Table 3).
Only one trial [22], compared the two screening
methods in terms of costs. Meltzer et al. concluded
that the two step approach was less expensive with
equivalent diagnostic power compared to the one
step approach [22]. Another limitation of our study
may be that lowering the diagnostic criteria in any
way that increases the incidence of the disease will
increase the false positive rate and include more
patients who are on the normal side of the spectrum
in the “diseased” category. And that will improve out-
comes in the “diseased” group, because those patients
aren’t really all “diseased”.
Different approaches and criteria for screening and
diagnosis of GDM have been proposed in the literature
(Table 1) [6,7,9–14]. The most common approaches are
the one step and the two step ones. Recent contro-
versy [6,7] has focused on the fact that IADPSG [7],
FIGO [11], and WHO [13], as well as other societies,
recommend the 75-gram 2hours test using the
IADPSG criteria, while ACOG [6] and ADA [9] recom-
mend the two step with 50 g 1 hour followed for
abnormals by the 3 h 100 g test using C&C criteria. The
argument against the one step approach has been
that it increases the incidence of GDM significantly,
without proven improvement in maternal and/or peri-
natal outcomes [6]. Our meta-analysis of RCTs revealed
that indeed, compared to the two step with 50 g
1 hour followed for abnormals by the 3 h 100 g test
using C&C criteria, the 75-gram 2hours test using the
IADPSG criteria is associated with significantly higher
incidence of GDM (13.9 versus 5.7%), but also with sig-
nificantly lower risk of PTB (3.7 versus 7.6%), cesarean
delivery (16.3 versus 22.0%), macrosomia (2.9 versus
6.9%), neonatal hypoglycemia (1.7 versus 4.5%), admis-
sion to NICU (4.4 versus 9.0%), and lower mean birth
Figure 3. Forest plot for the incidence of gestational diabetes mellitus. CI: confidence interval.
Figure 4. Forest plot for the incidence of gestational diabetes mellitus in subgroup analysis comparing the one step with 75 g
2 hours test using the International Association of Diabetes and Pregnancy Study Group (IADPSG) criteria, versus the two step with
50 g 1 hour followed for abnormals by the 3 h 100 g test using the Carpenter and Coustan (C&C) criteria. CI: confidence interval.
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weight by 135 grams (Tables 5 and 6). Clinically, these
are important outcomes, which would advise towards
recommending more globally the 75-gram 2hours test
using the IADPSG criteria, especially if confirmed by
more level 1 data, and by cost-effectiveness analyses
based on data from this meta-analysis. Data from our
meta-analysis may also explain, perhaps in small part,
the higher risks of some of these outcomes (e.g. PTB,
cesarean delivery, macrosomia) in the USA, where the
two step with 50 g 1 hour followed for abnormals by
the 3 h 100 g test using C&C criteria is commonly used
[6], compared to most European countries, where in
general the 75-gram 2 hours test using the IADPSG cri-
teria is more commonly used. The 75-gram 2 hours
test using the IADPSG criteria has the added benefit of
being only one step, and so giving potentially results
for GDM diagnosis sooner, but the downside of requir-
ing fasting for all women being screened for GDM.
In summary, the one and the two step approach
screening were associated with nonsignificant differ-
ence in the incidence of GDM. However, the one step
approach was associated with better maternal and peri-
natal outcomes, including lower risk of PTB, cesarean
delivery, macrosomia, LGA, neonatal hypoglycemia,
admission to NICU, and lower mean birth weight.
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